Evaluating CPI-0610 as Treatment of Patients With Myelofibrosis

July 14, 2020

Srdan Verstovsek, MD, PhD, discusses the potential role of CPI-0610 as treatment of patients with myelofibrosis.

Srdan Verstovsek, MD, PhD, medical oncologist and professor, Department of Leukemia, University of Texas MD Anderson Cancer Center, discusses the potential role of CPI-0610 as treatment of patients with myelofibrosis (MF).

CPI-0610 is a BET inhibitor, an epigenetic modifier. Verstovsek says epigenetic abnormalities are often present in patients with MF and is often associated with a loss of response to JAK inhibitors, such as ruxolitinib (Jakafi) and a shortened life expectancy.

The idea of using epigenetic modifiers is not new, as this has been tried with many other agents, including hypomethylating agents. CPI-0610 is being evaluated in a single-arm fusion in a phase 2 study following treatment with a JAK inhibitor. It is also being evaluated in addition to ruxolitinib after patients have achieved a stable dose of the JAK inhibitor. A third approach is evaluating CPI-0610 in combination with ruxolitinib.

Verstovsek concludes that this agent is under evaluation in many different scenarios in order to determine what its role should be in the treatment landscape of patients with MF.

<< View more resources and information regarding myelofibrosis